{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:06:15Z","timestamp":1771052775310,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T00:00:00Z","timestamp":1365206400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00280-013-2155-4","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T17:51:34Z","timestamp":1365184294000},"page":"1561-1565","source":"Crossref","is-referenced-by-count":56,"title":["Bevacizumab and central nervous system (CNS) hemorrhage"],"prefix":"10.1007","volume":"71","author":[{"given":"Nathalie","family":"Letarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda R.","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Villano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,6]]},"reference":[{"key":"2155_CR1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"2155_CR2","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"2155_CR3","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103\u20132111","journal-title":"Lancet"},{"key":"2155_CR4","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"2155_CR5","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184\u20132191","journal-title":"J Clin Oncol"},{"key":"2155_CR6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843\u2013850","journal-title":"J Clin Oncol"},{"key":"2155_CR7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","volume":"16","author":"B Besse","year":"2010","unstructured":"Besse B, Lasserre SF, Compton P et al (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16:269\u2013278","journal-title":"Clin Cancer Res"},{"key":"2155_CR8","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1200\/JCO.2009.22.0616","volume":"27","author":"MA Socinski","year":"2009","unstructured":"Socinski MA, Langer CJ, Huang JE et al (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27:5255\u20135261","journal-title":"J Clin Oncol"},{"key":"2155_CR9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3816\/CBC.2009.n.021","volume":"9","author":"SI Labidi","year":"2009","unstructured":"Labidi SI, Bachelot T, Ray-Coquard I et al (2009) Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 9:118\u2013121","journal-title":"Clin Breast Cancer"},{"key":"2155_CR10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1215\/15228517-2008-010","volume":"10","author":"CP Carden","year":"2008","unstructured":"Carden CP, Larkin JM, Rosenthal MA (2008) What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 10:624\u2013630","journal-title":"Neuro Oncol"},{"key":"2155_CR11","unstructured":"Bevacizumab prescribing information. In: Genentech Inc. San Francisco, CA. Available from http:\/\/www.gene.com\/gene\/products\/information\/pdf\/avastin-prescribing.pdf . Accessed 2 July 2012"},{"key":"2155_CR12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/annonc\/mdr148","volume":"23","author":"M Khasraw","year":"2012","unstructured":"Khasraw M, Holodny A, Goldlust SA, DeAngelis LM (2012) Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol 23:458\u2013463","journal-title":"Ann Oncol"},{"key":"2155_CR13","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2005.05.1573","volume":"24","author":"HX Chen","year":"2006","unstructured":"Chen HX, Mooney M, Boron M et al (2006) Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24:3354\u20133360","journal-title":"J Clin Oncol"},{"key":"2155_CR14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539\u20131544","journal-title":"J Clin Oncol"},{"key":"2155_CR15","first-page":"375","volume":"5","author":"TD Nguyen","year":"2007","unstructured":"Nguyen TD, Abrey LE (2007) Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol 5:375\u2013376 Discussion 377\u2013379","journal-title":"Clin Adv Hematol Oncol"},{"key":"2155_CR16","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.3748\/wjg.v17.i39.4440","volume":"17","author":"T Nishimura","year":"2011","unstructured":"Nishimura T, Furihata M, Kubo H et al (2011) Intracranial hemorrhage in patients treated with bevacizumab: report of two cases. World J Gastroenterol 17:4440\u20134444","journal-title":"World J Gastroenterol"},{"key":"2155_CR17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/JTO.0b013e318195a642","volume":"4","author":"T Tanvetyanon","year":"2009","unstructured":"Tanvetyanon T, Murtagh R, Bepler G (2009) Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol 4:268\u2013269","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2155-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2155-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2155-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:29Z","timestamp":1559038289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2155-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["2155"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2155-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,6]]}}}